250 mg CK-2017357

Phase 2

Cytokinetics, Incorporated (CYTK)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Amyotrophic Lateral Sclerosis

IONSION363

Phase 3

TEVJF40 mg glatiramer acetate

Phase 2

NRSNPlacebo

Phase 2

TEVA40 mg glatiramer acetate

Phase 2

View Full Landscape

Drug Information

Target Indication

Amyotrophic Lateral Sclerosis

Clinical Trial

NCT01089010

Last updated: 1/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CYTK

Cytokinetics, Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Standard of CarePhase 3

Heart Failure

AficamtenPhase 3

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Omecamtiv MecarbilPhase 3

Heart Failure With Reduced Ejection Fraction

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts